Abbott’s Expectation Accurate: U.S. Nutritional Product Sales Down
This article was originally published in The Tan Sheet
Executive Summary
International sales for Abbott Laboratories' nutritional products increased 13.4 percent in its fiscal 2007 first quarter, but the firm's expectation of a decrease in its U.S. nutritional sales proved accurate
You may also be interested in...
Similac, Pediasure Drive Abbott’s Ross Sales In 2007
Similac, PediaSure and the launch of NutriPals bars and shakes drove sales by Abbott Laboratories' Ross U.S. Nutritionals unit up 3 percent to $624 million in its fourth quarter, according to Abbott President and COO Rick Gonzalez
Abbott Singapore Nutritionals Plant Will Be Operational In 2008, Firm Says
The construction of a $280 mil. nutritional powder manufacturing plant in Singapore by Abbott Laboratories will help the company achieve its goal of expanding its presence in the Asian nutritionals market, the firm said during a groundbreaking ceremony April 21
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.